At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
VRDN Viridian Therapeutics, Inc.
Market Closed 07-24 16:00:00 EDT
19.27
+0.01
+0.05%
盘后19.20
-0.07-0.36%
19:34 EDT
High19.45Low19.00Vol1.52M
Open19.39D1 Closing19.26Amplitude2.36%
Mkt Cap2.13BTradable Cap2.03BTotal Shares110.43M
T/O29.20MT/O Rate1.44%Tradable Shares105.28M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Wells Fargo Reaffirms Their Buy Rating on Viridian Therapeutics (VRDN)
TIPRANKS  ·  07-20
Wells Fargo Reaffirms Their Buy Rating on Viridian Therapeutics (VRDN)
Wedbush Sticks to Its Buy Rating for Viridian Therapeutics (VRDN)
TIPRANKS  ·  07-13
Wedbush Sticks to Its Buy Rating for Viridian Therapeutics (VRDN)
Viridian Therapeutics (VRDN) Could Be 87% Below Fair Value After FDA Approval
Simply Wall St.  ·  07-11
Viridian Therapeutics (VRDN) Could Be 87% Below Fair Value After FDA Approval
The Bull Case For Viridian Therapeutics (VRDN) Could Change Following FDA Approval Of Lumvoa For Thyroid Eye Disease
Simply Wall St.  ·  07-06
The Bull Case For Viridian Therapeutics (VRDN) Could Change Following FDA Approval Of Lumvoa For Thyroid Eye Disease
Viridian Therapeutics (VRDN) Gets a Buy from RBC Capital
TIPRANKS  ·  06-30
Viridian Therapeutics (VRDN) Gets a Buy from RBC Capital
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday Amid Hopes for Renewed US-Iran Diplomacy
MT Newswires Live  ·  06-29
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday Amid Hopes for Renewed US-Iran Diplomacy
Viridian Therapeutics Exec Says the Wholesale Acquisition Cost for Five Infusions of Lumvoa is About $450,000 for a Typical 75‑kg Patient
THOMSON REUTERS  ·  06-29
Viridian Therapeutics Exec Says the Wholesale Acquisition Cost for Five Infusions of Lumvoa is About $450,000 for a Typical 75‑kg Patient
Viridian Therapeutics Exec Says Five Infusions of Its Thyroid Eye Disease Drug Lumvoa are Priced Roughly in Line with Eight Infusions of Amgen’s Tepezza - Conf Call
THOMSON REUTERS  ·  06-29
Viridian Therapeutics Exec Says Five Infusions of Its Thyroid Eye Disease Drug Lumvoa are Priced Roughly in Line with Eight Infusions of Amgen’s Tepezza - Conf Call
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN) and Fortrea Holdings Inc. (FTRE)
TIPRANKS  ·  06-29
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN) and Fortrea Holdings Inc. (FTRE)
U.S. Stocks on the Move-spacex, Charter
Reuters  ·  06-29
U.S. Stocks on the Move-spacex, Charter
US Stocks-wall St Climbs as Mideast Tensions Ease, Comcast Surges on Spin-off Plan
Reuters  ·  06-29
US Stocks-wall St Climbs as Mideast Tensions Ease, Comcast Surges on Spin-off Plan
Stock Market Today: Dow Jones, S&P 500 Futures Gain As Trump Admin Says US, Iran Will 'Stand Down'—Verizon, HP, Universe Pharmaceuticals In Focus
Benzinga  ·  06-29
Stock Market Today: Dow Jones, S&P 500 Futures Gain As Trump Admin Says US, Iran Will 'Stand Down'—Verizon, HP, Universe Pharmaceuticals In Focus
Viridian Therapeutics Shares up 10.8% Premarket After U.S. FDA Greenlights Co's Thyroid Eye Disease Drug
THOMSON REUTERS  ·  06-29
Viridian Therapeutics Shares up 10.8% Premarket After U.S. FDA Greenlights Co's Thyroid Eye Disease Drug
Concentrix, AeroVironment And 3 Stocks To Watch Heading Into Monday
Benzinga  ·  06-29
Concentrix, AeroVironment And 3 Stocks To Watch Heading Into Monday
Why Viridian Therapeutics (VRDN) Is Up 7.6% After FDA Clears First All‑Stage Thyroid Eye Drug
Simply Wall St.  ·  06-29
Why Viridian Therapeutics (VRDN) Is Up 7.6% After FDA Clears First All‑Stage Thyroid Eye Drug
Analysts Are Bullish on These Healthcare Stocks: Viridian Therapeutics (VRDN), Genfleet Therapeutics (Shanghai), Inc. Class H (HK:2595)
TIPRANKS  ·  06-28
Analysts Are Bullish on These Healthcare Stocks: Viridian Therapeutics (VRDN), Genfleet Therapeutics (Shanghai), Inc. Class H (HK:2595)
US FDA Greenlights Viridian's Eye Disease Drug
Reuters  ·  06-27
US FDA Greenlights Viridian's Eye Disease Drug
Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
THOMSON REUTERS  ·  06-27
Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
Viridian’s VRDN-003 Thyroid Eye Disease Trial Reaches Completion, Resetting the Risk/Reward for Investors
TIPRANKS  ·  06-26
Viridian’s VRDN-003 Thyroid Eye Disease Trial Reaches Completion, Resetting the Risk/Reward for Investors
Viridian Therapeutics (VRDN) Stock Could Be 84.84% Below Fair Value After Institutional Buying
Simply Wall St.  ·  06-19
Viridian Therapeutics (VRDN) Stock Could Be 84.84% Below Fair Value After Institutional Buying

Introduction

Company Name.
Viridian Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-002 and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-004, a discovery-stage therapeutic antibody program for rare disease; and VRDN-005 and VRDN-006, a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. is headquartered in Waltham, Massachusetts.
Issue price:
--